AUF-1 mediates inhibition by nitric oxide of lipopolysaccharide-induced matrix metalloproteinase-9 expression in cultured astrocytes

Journal of Neuroscience Research

Volumn 84, Issue 2, 2006, Pages 360-369

  Liu, Wenlan ^a   Rosenberg, Gary A ^b   Liu, Ke Jian ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Astrocytes; AUF 1; Lipopolysaccharide; Matrix metalloproteinases; Nitric oxide

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GELATINASE B; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NITRIC OXIDE; UO 126;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; CELL CULTURE; CONTROLLED STUDY; DATA ANALYSIS; DEGENERATIVE DISEASE; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; ASTROCYTES; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN D; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; NEUROTRANSMITTER AGENTS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 33746430917     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.20895     Document Type: Article

References (60)

1. Akool el S, Kleinen H, Hamada FM, Abdelwahab MH, Forstermann U, Pfeilschifter J, Eberhardt W. 2003. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 23:4901-4916.
2. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. 2000. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1689.
3. Barone FC, Feuerstein GZ. 1999. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 19:819-834.
4. Boje KM, Jaworowicz D Jr, Raybon JJ. 2003. Neuroinflammatory role of prostaglandins during experimental meningitis: evidence suggestive of an in vivo relationship between nitric oxide and prostaglandins. J Pharmacol Exp Ther 304:319-325.
5. Brennan CM, Steitz JA. 2001. HuR and mRNA stability. Cell Mol Life Sci 58:266-277.
6. Chan PH. 2001. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21:2-14.
7. Cuschieri J, Maier RV. 2005. Mitogen-activated protein kinase (MAPK). Crit Care Med 33(Suppl 12):S417-S419.
8. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, Tokes ZA, Tsai J, McCuskey RS. 2003. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 38:900-908.
9. Droge W. 2002. Free radicals in the physiological control of cell function. Physiol Rev 82:47-95.
10. Eagleton MJ, Peterson DA, Sullivan W, Roelofs KJ, Ford JA, Stanley JC, Upchurch GR Jr. 2002. Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression. J Surg Res 104:15-21.
11. Eberhardt W, Beeg T, Beck KF, Walpen S, Gauer S, Bohles H, Pfeilschifter J. 2000. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 57:59-69.
12. Eberhardt W, Akool el S, Rebhan J, Frank S, Beck KF, Franzen R, Hamada FM, Pfeilschifter J. 2002. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability. J Biol Chem 277:33518-33528.
13. Ehrenman K, Long L, Wagner BJ, Brewer G. 1994. Characterization of cDNAs encoding the murine A + U-rich RNA-binding protein AUF1. Gene 149:315-319.
14. Emonard H, Grimaud JA. 1990. Matrix metalloproteinases. A review. Cell Mol Biol 36:131-153.
15. Fan XC, Steitz JA. 1998. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 17:3448-3460.
16. Floyd RA. 1999. Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med 26:1346-1355.
17. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. 1999. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 842:92-100.
18. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. 2001. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 21:1393-1400.
19. Gottschall PE, Deb S. 1996. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 3:69-75.
20. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA. 2002. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186-1190.
21. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D. 1998. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 17:213-225.
22. Gurjar MV, DeLeon J, Sharma RV, Bhalla RC. 2001a. Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells. J Appl Physiol 91:1380-1386.
23. Gurjar MV, Deleon J, Sharma RV, Bhalla RC. 2001b. Role of reactive oxygen species in IL-1 beta-stimulated sustained ERK activation and MMP-9 induction. Am J Physiol Heart Circ Physiol 281:H2568-H2574.
24. Gursoy-Ozdemir Y, Can A, Dalkara T. 2004. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 35:1449-1453.
25. Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B. 2004. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 23:4993-5003.
26. Iadecola C. 1997. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 20:132-139.
27. Jung SW, Lee MH, Kim YC, Paik SG, Choi YH, Kim YS, Kang KI. 2004. Modulation of the transactivation function of nuclear factor-kappaB by lipopolysaccharide in RAW264.7 macrophages. Int J Oncol 25:1081-1087.
28. Knipp BS, Ailawadi G, Ford JW, Peterson DA, Eagleton MJ, Roelofs KJ, Hannawa KK, Deogracias MP, Ji B, Logsdon C, Graziano KD, Simeone DM, Thompson RW, Henke PK, Stanley JC, Upchurch GR Jr. 2004. Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-kappaB and activator protein-1 activity. J Surg Res 116:70-80.
29. Lander HM, Jacovina AT, Davis RJ, Tauras JM. 1996. Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J Biol Chem 271:19705-19709.
30. Lapucci A, Donnini M, Papucci L, Witort E, Tempestini A, Bevilacqua A, Nicolin A, Brewer G, Schiavone N, Capaccioli S. 2002. AUF1 Is a bcl-2 A + U-rich element-binding protein involved in bcl-2 mRNA destabilization during apoptosis. J Biol Chem 277:16139-16146.
31. Le DM, Besson A, Fogg DK, Choi KS, Waisman DM, Goodyer CG, Rewcastle B, Yong VW. 2003. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 23:4034-4043.
32. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, Cheong JH, Ryu JH, Ko KH. 2003. Induction of matrix metalloproteinase-9 (MMP-9) in H-popolysaccharide- stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41:15-24.
33. Lin S, Wang W, Wilson GM, Yang X, Brewer G, Holbrook NJ, Gorospe M. 2000. Down-regulation of cyclin D1 expression by prostaglandin A is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol 20:7903-7913.
34. Loflin P, Chen CY, Shyu AB. 1999. Unraveling a cytoplasmic role for hnRNP D in the in vivo mRNA destabilization directed by the AU-rich element. Genes Dev 13:1884-1897.
35. Maier CM, Hsieh L, Yu F, Bracci P, Chan PH. 2004. Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia. Stroke 35:1169-1174.
36. Marcet-Palacios M, Graham K, Cass C, Befus AD, Mayers I, Radomski MW. 2003. Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J Pharmacol Exp Ther 307:429-436.
37. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, Gorospe M. 2003. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A 100:8354-8359.
38. Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, Rogers JH. 2002. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 100:103-117.
39. Mun-Bryce S, Rosenberg GA. 1998a. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 274:R1203-R1211.
40. Mun-Bryce S, Rosenberg GA. 1998b. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18:1163-1172.
41. Nithipatikom K, Holmes BB, Isbell MA, Hanke CJ, Gomez-Sanchez CE, Campbell WB. 2005. Measurement of steroid synthesis in zona glomerulosa cells by liquid chromatography-electrospray ionization-mass spectrometry: inhibition by nitric oxide. Anal Biochem 337:203-210.
42. Novaro V, Colman-Lerner A, Ortega FV, Jawerbaum A, Paz D, Lo Nostro F, Pustovrh C, Gimeno MF, Gonzalez E. 2001. Regulation of metalloproteinases by nitric oxide in human trophoblast cells in culture. Reprod Fertil Dev 13:411-420.
43. Okamoto T, Valacchi G, Gohil K, Akaike T, van der Vliet A. 2002. S-nitrosothiols inhibit cytokine-mediated induction of matrix metalloproteinase-9 in airway epithelial cells. Am J Respir Cell Mol Biol 27:463-473.
44. Peng SS, Chen CY, Xu N, Shyu AB. 1998. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J 17:3461-3470.
45. Pfefferkorn T, Rosenberg GA. 2003. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34:2025-2030.
46. Planas A, Clara A, Pou JM, Vidal-Barraquer F, Gasol A, de Moner A, Contreras C, Marrugat J. 2001. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men. Int J Obes Rel Metab Disord 25:1068-1070.
47. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. 1998. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020-1030.
48. Rosenberg GA. 2002. Matrix metalloproteinases in neuroinflammation. Glia 39:279-291.
49. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A. 2001. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893:104-112.
50. Simon C, Goepfert H, Boyd D. 1998. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92, 000 type IV collagenase secretion and in vitro invasion. Cancer Res 58:1135-1139.
51. Sinha I, Hannawa KK, Ailawadi G, Woodrum DT, Ford JW, Henke PK, Stanley JC, Eagleton MJ, Upchurch GR Jr. 2006. The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. Ann Vasc Surg 20:92-98.
52. Togo T, Katsuse O, Iseki E. 2004. Nitric oxide pathways in Alzheimer's disease and other neurodegenerative dementias. Neurol Res 26:563-566.
53. Wang D, Yu X, Brecher P. 1998. Nitric oxide and N-acetylcysteine inhibit the activation of mitogen-activated protein kinases by angiotensin II in rat cardiac fibroblasts. J Biol Chem 273:33027-33034.
54. Wang H, MacNaughton WK. 2005. Overexpressed beta-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells. Cancer Res 65:8604-8607.
55. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH. 2003. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313-1317.
56. Wang XY, Hoyle PE, McCubrey JA. 1998. Characterization of proteins binding the 3′ regulatory region of the IL-3 gene in IL-3-dependent and autocrine-transformed hematopoietic cells. Leukemia 12:520-531.
57. Wetzel M, Rosenberg GA, Cunningham LA. 2003. Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur J Neurosci 18:1050-1060.
58. Wu CY, Hsieh HL, Jou MJ, Yang CM. 2004. Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-kappa B in interleukin-1 beta-induced matrix metalloproteinase-9 expression in rat brain astrocytes. J Neurochem 90:1477-1488.
59. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. 2003. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112:1533-1540.
60. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. 1998. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75-80.